Drug profile · INN
insulin lispro recombinant
HUMALOG KWIKPEN
insulin lispro recombinant (HUMALOG KWIKPEN) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — insulin lispro recombinant
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
insulin lispro recombinant (HUMALOG KWIKPEN) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is insulin lispro recombinant?
insulin lispro recombinant (HUMALOG KWIKPEN) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for insulin lispro recombinant?
HUMALOG KWIKPEN is a marketed brand name for insulin lispro recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin lispro recombinant?
insulin lispro recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.